Albendazole versus metronidazole in the treatment of adult giardiasis: a randomized, double-blind, clinical trial.

BACKGROUND: Albendazole (ABZ) is a benzimidazole carbamate compound currently in use for human medical practice against enterobiasis and soil-transmitted helminthiasis (STH); However, its spectrum of activity is broad and goes beyond these infections. OBJECTIVE: This study compares the efficacy and safety of ABZ versus metronidazole (MTZ) in human giardiasis. RESEARCH DESIGN AND METHODS: A randomized, double-blind, clinical trial was carried out at the Centre of Hygiene, Epidemiology and Microbiology in Matanzas City, Cuba. Adult patients with confirmed symptomatic G. duodenalis mono-infection were randomly assigned to receive either ABZ [400 mg daily (n = 75)] or MTZ [250 mg t.i.d. (n = 75)], both for 5 days. Follow-up fecal samples were obtained at 3, 5, 7 days after treatment end. RESULTS: The efficacy was similar for both treatment groups: ABZ (82.6%) and MTZ (85.3%); p > 0.05. Side-effects including bitter taste, headache, vomiting and dizziness were significantly higher in the MTZ group. Abdominal pain was significantly higher in ABZ group. CONCLUSION: ABZ was found as effective as MTZ in the treatment of G. duodenalis infections in adult patients from Cuba and could be a useful drug in areas where co-infection with STH infections is common.

Effects of dietary supplementation with medicinal fungus in fasting glycemia levels of patients with colorectal cancer: a randomized, double-blind, placebo-controlled clinical study.

OBJECTIVE: The objective of this study was to evaluate the effects of dietary supplementation with Agaricus sylvaticus medicinal fungus in fasting glycemia of post-surgery patients with colorectal cancer. SCOPE: Proctology Ambulatory of Federal District Base Hospital-Brazil. SUBJECTS: Fifty-six colorectal cancer patients in postsurgery phase, stadiums phase I, II and II, which followed specific criteria of inclusion and exclusion. INTERVENTIONS: All patients were randomized in two groups: supplemented with Agaricus sylvaticus fungus (30 mg/kg/day) and placebo, and were followed up for six months. Subjects were divided later on according to BMI--Body Mass Index, sex and stage. Three fasting glycemia evaluations were carried out throughout the treatment. RESULTS: Subjects presented BMI medium = 24.65 kg/m2 (57.1% women and 42.9% men). The placebo group (average age 59.14 +/- 12.95 years) had initial glycemia levels of 94.36 +/- 15.34 mg/dL, after three months 98.12 +/- 15.54 mg/dL (p = 0.03) and in the sixth month 98.52 +/- 9.03 mg/dL (p = 0.01). The supplemented group (average age of 56.34 +/- 15.53 years) had initial glycemia levels of 95.92 +/- 11.64 mg/dL, after three months 94.88 +/- 12.24 mg/dL (p = 0.65) and, in the sixth month, a significant reduction to 92.86 +/- 6.82 mg/dL (p = 0.01). CONCLUSION: The results suggest that the dietary supplementation with Agaricus sylvaticus medicinal fungus can significantly reduce fasting glycemia levels of colorectal cancer patients in post-surgery phase.

Metabolic and hematological effects of dietary supplementation with arginine on rats bearing ascitic Walker 256 tumor.

The notion of using supplementary quantities of arginine for nutritional support in patients with cancer has been evaluated not only as supplement intake of nitrogen substrate but also for its immunopharmacological effects capable of improving the patient's prognosis. The aim of the present study is to evaluate the effects of dietary supplementation with arginine on metastatic dissemination, amino acid metabolism, hematological functions of rats with Walker 256 ascitic tumor. Animals were inoculated intraperitoneally with approximately 4 million cells. Nutritional solutions containing 4 or 6% arginine or just a control diet without added arginine, were administered to the animals via esophagic gavages. The rate of metastasis was lower in animals supplemented with arginine at 4 and 6%. Amino acid metabolism was stimulated in tumor-bearing animals after receiving 4 or 6% arginine, demonstrated by significant increase of arginine, ornithine, citrulline, proline and histidine levels in the blood (p < or = 0.001) when compared to the control diet group. Anemia was less severe in tumor-bearing animals that received arginine supplementation. The findings suggest that arginine supplementation at 6% may have a beneficial effect on to the host, besides its pharmacological action.

Maillard's reaction in parenteral solutions supplemented with arginine

Arginine, as a basic amino acid, can alter the pH of a parenteral solution and consequently to interfere in the stability of other amino acids. The objective of this study was to analyze the chemical stability of amino acids in solutions for parenteral nutrition with arginine supplementation. Amino acids concentrations were determined using an amino acid analyzer in intervals of 12, 36, 72 hours, 7 and 28 days. Storage temperatures were -20 degrees C, 5 degrees C and 25 degrees C. A decrease was observed (p < 0.05) in the concentrations of threonine, methionine, isoleucine, leucine, proline and lysine on the 28th day of study, in the solutions kept at 25 degrees C. The side chains of threonine, methionine, isoleucine, leucine, proline and lysine have hydrophobic groups, which renders them less soluble in water when compared to amino acids that have polar side chains. The degradation of lysine was significant in the sample of parenteral nutrition supplemented with arginine, possibly due to the fact that the solution's pH was between 7.5 and 7.6, therefore facilitating the Maillard reaction between lysine and glucose.